Reshape Lifesciences Inc.

Doing business as (A Development Stage Company)

UEI
YL7CYVSRUN55
CAGE
61TK5
Primary NAICS
813990 Other Similar Organizations (except Business, Professional, Labor, and Political Organizations)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Small Business Joint Venture
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
medtimo.com
Founded
2025
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
SIC code
59 Miscellaneous Retail
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Implant VA25717P0447 Veterans Integrated Service Network 17 (VHA) $17,000
Surgical implants VA25716P3687 Veterans Integrated Service Network 17 (VHA) $17,000
Implant VA25716P3541 Veterans Integrated Service Network 17 (VHA) $17,000
Surgical implants VA25716P3180 Veterans Integrated Service Network 17 (VHA) $17,000
Surgical implants VA25716P2929 Veterans Integrated Service Network 17 (VHA) $17,000

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Grant subawards

Prime recipient Prime award Amount Awarded
University Of Southern California HORNET Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) Admin Supplement 2 U41NS129514 $216,627

Similar vendors

About the company

Reshape Lifesciences Inc. is a corporate for-profit organization registered in SAM.gov since June 17, 2010, with active registration through August 1, 2025. Classified as a small business joint venture, the company appears to be focused on developing innovative medical technologies, specifically targeting diabetes-related treatments and neurological interventions. The organization is in a development stage, concentrating on research and development of advanced medical therapies that involve neurostimulation and targeted nerve modulation techniques.

The company has received multiple federal grant awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program. Their grant-funded research has consistently centered on developing novel therapeutic approaches for type 2 diabetes mellitus, with a specific focus on targeted dual neuromodulation (TDN) therapies. Specific research projects include developing implantable pulse generator systems that can block and stimulate specific branches of the vagus nerve to improve glycemic control, creating high-definition endoscopic ultrasound navigation techniques for precise nerve stimulation, and designing hypoglycemia vagal nerve stimulation (HVNS) systems to help manage blood glucose levels. These research efforts are conducted through Phase I Small Business Innovation Research (SBIR) grants, with each project aimed at demonstrating feasibility, minimizing off-target physiological effects, and developing potential commercial medical interventions for diabetes management.

Quick answers

Is Reshape Lifesciences Inc. registered in SAM.gov?

Reshape Lifesciences Inc.'s SAM.gov registration expired on July 22, 2026.

What is Reshape Lifesciences Inc.'s CAGE code?

Reshape Lifesciences Inc.'s CAGE code is 61TK5, and its Unique Entity ID (UEI) is YL7CYVSRUN55.

What is Reshape Lifesciences Inc.'s most recent federal award?

Reshape Lifesciences Inc.'s most recent federal grant award is Diabetic targeted dual neuromodulation parametric optimization (R43DK137628), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on August 20, 2024.

On GovTribe

See Reshape Lifesciences Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe